fda glp‑1 restrictions
Stop Losing Control With Prescription Weight Loss
Answer: The FDA is tightening rules on compounded GLP-1 weight-loss drugs to protect patients from unsafe, unapproved formulations. The agency’s latest move removes semaglutide, tirzepatide and liraglutide from the 503B bulks list, meaning most pharmacies can no longer produce them in bulk without special licensing. This shift follows a